MingMed to Present at the 40th Annual J.P. Morgan Healthcare Conference

GUANGZHOU, China, Jan. 5, 2022 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing First-in-Class pharmaceutical products, today announced that Ms. Liza Ko, Chief Financial Officer of the company, has been invited to present at the 40^th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 08:00 AM ET (09:00 PM, Jan. 10, 2022 Beijing Time), on the company and its latest R&D progress.

Registered participants of the J.P. Morgan Healthcare Conference may view the presentation online using the link below. The replay will be available for 30 days post the conference:

https://jpmorgan.metameetings.net/events/healthcare22/sessions/40605-mingmed-biotechnology-co-ltd/webcast?gpu_only=true&kiosk=true

About MingMed

MingMed Biotechnology is a clinical stage company dedicated to developing First-in-Class pharmaceutical products. Our team is formed by global top-notch scientists and specialists, while our scientific committee consists of influential scientists in the world. The company has already made world-class breakthroughs in developing novel therapies in the fields of ophthalmology, medical aesthetics, immuno-oncology and cell therapy. There are currently over 10 products in the R&D pipeline, most of which are First-in-Class medications for unmet medical needs and are at clinical stage.

For more information, please visit: www.ming-med.com

Media Contact: Jan Zhou
Email Address: [email protected]

SOURCE MingMed Biotechnology